The CD1d-dependent presentation of lipid antigens to natural killer T (NKT) cells is an integral part of the innate immune system. However, the development of anticancer therapies based on NKT-cell agonists has had limited success so far. Humanizing mice with respect to the CD1d/NKT antigen presentation system will provide a tool to identify novel lipids that exert antineoplastic functions by targeting NKT cells before the initiation of costly and lengthy clinical trials.
Keywords: CD1d; anticancer therapy; humanized mice; iNKT cells; immunotherapy.